Episode
A conversation with Dr. Jeff Singer, Senior Fellow at the Cato Institute
We discuss the proposed changes to the CDC opioid prescribing guidelines and challenge false notions on opioids, prohibition, and addiction. ...
A conversation with Miss Bev Schechtman, Vice President of The Doctor Patient Forum
We discuss Miss Schechtman's journey from a patient to a patient advocate, who through her platform now empowers patients suffering ...
A conversation with Mr. David Levine, co-Chair of Co-Chair Science Writers in New York
We discuss the past, present, and future of healthcare journalism, gleaning lessons learned over the pandemic to predict upcoming trends. ...
A conversation with Dr. Nabarun Dasgupta, Gillings Innovation Fellow and Senior Scientist at the UNC Injury Prevention Research Center
We discuss Dr. Dasgupta's research paper, Inches, Centimeters, and Yards, to learn about inconsistencies in the definition of Morphine Milligram ...
A conversation with Dr. Mark Garofoli, director of experiential learning and clinical pharmacy
Dr. Mark Garofoli is a 2004 graduate from the Pitt School of Pharmacy and a 2008 graduate of the Strayer ...
A conversation with Dr. John Whyte, CMO of WebMD, on the state of healthcare media
Dr. John Whyte is a popular physician and writer who has been communicating to the public about health issues for ...
A conversation with Dr. Adalja, subject matter expert in Healthcare Security
Dr. Adalja is a Senior Scholar at the Johns Hopkins Center for Health Security, an Adjunct Assistant Professor at the ...
A conversation with Dr. Yeldandi, Director of SHARE India
Dr. Yeldandi is the Director of SHARE India and an infectious disease specialist with over 25 years of experience in ...
A conversation with Mr. Ron Chapman II, a top legal mind in healthcare compliance and opioid litigation
Mr. Ron Chapman II began his career as an officer in the U.S. Marine Corps and was deployed to combat ...
A conversation with Dr. Asha Shajahan, thought leader combating healthcare misinformation
Dr. Shajahan is leading the conversation on healthcare misinformation and overcoming vaccine hesitancy through a unique blend of policy leadership ...
A conversation with Sharon Goldfarb, Doctor of Nursing Practice and vaccine advocate at This Is Our Shot
Dr. Goldfarb has been an advocate of disenfranchised patients for decades, beginning with the AIDS epidemic and continuing through the ...
A conversation with Dr. Rotenstein, national expert in healthcare burnout
A conversation with Dr. Rotenstein, national expert in healthcare burnout Dr. Rotenstein is a primary care physician, healthcare leader, and ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read morePopular
-
The IRA’s Drug Negotiation Mechanism Meets the Rebate Industrial Complex
-
Two Platforms, Two Theories of Change in Hospital Pricing
-
The Price Is Right, Theoretically: What Turquoise Health Actually Reveals About Hospital Markets
-
The Payer’s Dilemma: Choosing Between Negotiation Intelligence and Market Disclosure
-
Turquoise Health and the Cartography of Hidden Prices
